BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32479245)

  • 21. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs.
    Bartuzi D; Kaczor AA; Matosiuk D
    Methods Mol Biol; 2018; 1705():297-319. PubMed ID: 29188568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
    Burford NT; Watson J; Bertekap R; Alt A
    Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripherally acting opioid analgesics and peripherally-induced analgesia.
    Martínez V; Abalo R
    Behav Pharmacol; 2020 Apr; 31(2&3):136-158. PubMed ID: 32168025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Modulators: A Side Door.
    Abood ME
    J Med Chem; 2016 Jan; 59(1):42-3. PubMed ID: 26645411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors.
    Wootten D; Miller LJ
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():89-107. PubMed ID: 31454292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of opioid-induced pain and antinociceptive tolerance: signal transduction.
    Colpaert FC
    Pain; 2002 Feb; 95(3):287-288. PubMed ID: 11839428
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging Insights into Mu Opioid Pharmacology.
    Pasternak GW; Childers SR; Pan YX
    Handb Exp Pharmacol; 2020; 258():89-125. PubMed ID: 31598835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
    Lu S; He X; Ni D; Zhang J
    J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric small molecule modulators of nuclear receptors.
    Meijer FA; Leijten-van de Gevel IA; de Vries RMJM; Brunsveld L
    Mol Cell Endocrinol; 2019 Apr; 485():20-34. PubMed ID: 30703487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biased Opioid Receptor Ligands: Gain without Pain.
    Ranjan R; Pandey S; Shukla AK
    Trends Endocrinol Metab; 2017 Apr; 28(4):247-249. PubMed ID: 28110810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioids for chronic pain: molecular and genomic basis of actions and adverse effects.
    Ahmedzai SH; Boland J
    Curr Opin Support Palliat Care; 2007 Aug; 1(2):117-25. PubMed ID: 18685352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antinociceptive and nociceptive actions of opioids.
    Ossipov MH; Lai J; King T; Vanderah TW; Malan TP; Hruby VJ; Porreca F
    J Neurobiol; 2004 Oct; 61(1):126-48. PubMed ID: 15362157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief.
    Janecka A; Gentilucci L
    Future Med Chem; 2014; 6(18):2093-101. PubMed ID: 25531970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current strategies toward safer mu opioid receptor drugs for pain management.
    Ehrlich AT; Kieffer BL; Darcq E
    Expert Opin Ther Targets; 2019 Apr; 23(4):315-326. PubMed ID: 30802415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physicochemical and Pharmacological Characterization of Permanently Charged Opioids.
    Mazak K; Noszal B; Hosztafi S
    Curr Med Chem; 2017; 24(33):3633-3648. PubMed ID: 28685673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multitarget opioid ligands in pain relief: New players in an old game.
    Turnaturi R; Aricò G; Ronsisvalle G; Parenti C; Pasquinucci L
    Eur J Med Chem; 2016 Jan; 108():211-228. PubMed ID: 26656913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype.
    Drakopoulos A; Moianos D; Prifti GM; Zoidis G; Decker M
    ChemMedChem; 2022 Jul; 17(14):e202200169. PubMed ID: 35560796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human opiorphin: the lack of physiological dependence, tolerance to antinociceptive effects and abuse liability in laboratory mice.
    Popik P; Kamysz E; Kreczko J; Wróbel M
    Behav Brain Res; 2010 Nov; 213(1):88-93. PubMed ID: 20438769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABA
    Lewter LA; Fisher JL; Siemian JN; Methuku KR; Poe MM; Cook JM; Li JX
    ACS Chem Neurosci; 2017 Jun; 8(6):1305-1312. PubMed ID: 28150939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.